Увійти

Готові списки джерел за темами / Chronic liver disease and Non invasive marker

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Chronic liver disease and Non invasive marker"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Chronic liver disease and Non invasive marker".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Chronic liver disease and Non invasive marker"

1

Dr., Muhammad Adnan Bawany *. Dr. Tariq Zaffar Shaikh Dr Abdul Rahim Memon Dr. Syed Zulfiquar Ali Shah Dr. Jesse Suarez Dr. Samreen. "NON INVASIVE MARKER (AST/ALT RATIO) TO PREDICT FIBROSIS IN PATIENTS WITH CHRONIC LIVER DISEASE." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4358–61. https://doi.org/10.5281/zenodo.1064339.

Повний текст джерела

Анотація:

Objective: To evaluate the AST/ALT ratio to predict fibrosis in patients with chronic liver disease at tertiary care hospital Patients and Methods: Total fifty patients, of 12 to 50 years either gender had chronic liver disease by positive HCV RNA PCR and/or HBs Ag, and had liver biopsy done for evaluation purposes were enrolled and entered in this six months cross sectional study after informed consent. The brief history was taken and relevant clinical examination was performed while the laboratory investigations includes liver function test, serum albumin, ultrasound abdomen, prothrombin tim

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Dr., Abdul Rahim Memon *. Dr. Nand Lal Seerani Dr. Majid Ali Soomro Dr. Imran Karim Dr. Ramon A. Docobo and Dr. Samreen. "FORNS INDEX TO PREDICT FIBROSIS IN PATIENTS WITH CHRONIC LIVER DISEASE." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4362–65. https://doi.org/10.5281/zenodo.1064341.

Повний текст джерела

Анотація:

Objective: To estimate the Forns index to predict fibrosis in patients with chronic liver disease at tertiary care hospital Patients and Methods: Total Fifty patients, of 12 to 50 years either gender had chronic liver disease by positive HCV RNA PCR and/or HBsAg, and had liver biopsy done for evaluation purposes were enrolled and entered in this six months cross sectional study after informed consent. The brief history was taken and relevant clinical examination was performed while the laboratory investigations include latelet count, γ-glutamyl transferase (GGT), and cholesterol levels.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Orasan, Olga Hilda, George Ciulei, Angela Cozma, Madalina Sava, and Dan Lucian Dumitrascu. "Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies." Medicine and Pharmacy Reports 89, no. 1 (2016): 24–31. http://dx.doi.org/10.15386/cjmed-554.

Повний текст джерела

Анотація:

Chronic liver diseases represent a significant public health problem worldwide. The degree of liver fibrosis secondary to these diseases is important, because it is the main predictor of their evolution and prognosis.Hyaluronic acid is studied as a non-invasive marker of liver fibrosis in chronic liver diseases, in an attempt to avoid the complications of liver puncture biopsy, considered the gold standard in the evaluation of fibrosis. We review the advantages and limitations of hyaluronc acid, a biomarker, used to manage patients with chronic viral hepatitis B or C infection, non-alcoholic f

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Loomba, Rohit, and Leon A. Adams. "Advances in non-invasive assessment of hepatic fibrosis." Gut 69, no. 7 (2020): 1343–52. http://dx.doi.org/10.1136/gutjnl-2018-317593.

Повний текст джерела

Анотація:

Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts the risk of future liver-related morbidity and thus need for treatment, monitoring and surveillance. Non-invasive fibrosis tests (NITs) overcome many limitations of liver biopsy and are now routinely incorporated into specialist clinical practice. Simple serum-based tests (eg, Fibrosis Score 4, non-alcoholic fatty liver disease Fibrosis Score) consist of readily available biochemical surrogates and clinical risk factors for liver fibrosis (eg, age and sex). These have been extensively validated acros

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Mihaylov, R., B. Pencheva, D. Stoeva, and A. Ruseva. "Non-invasive Diagnostics of Liver Fibrosis." Acta Medica Bulgarica 44, no. 1 (2017): 50–56. http://dx.doi.org/10.1515/amb-2017-0009.

Повний текст джерела

Анотація:

Abstract Detecting new units of pathogenesis in the liver fibrosis due to alcoholism, chronic viral Hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), autoimmune, parasitic and metabolic diseases and other, reveals perspective for new non-invasive serum biomarkers. In fibrosis, from the wide variety of markers enzymes, proteins and cytokines are mainly used. While direct biomarkers reflect the stage of fibrosis and fibrinogenesis, indirect markers allow assessment of the general liver functions. The combination of direct and indirect markers increases the diagnostic reliability and

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Nachit, Maxime. "Precision imaging in chronic liver disease management." Acta Gastro Enterologica Belgica 88, no. 1 (2025): 61. https://doi.org/10.51821/88.1.14128.

Повний текст джерела

Анотація:

Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over a quarter of the global population, with up to 30% developing Metabolic Dysfunction-Associated Steatohepatitis (MASH), a progressive form that can silently lead to fibrosis, cirrhosis, and liver cancer. Current diagnostic methods, including blood-based scores and imaging, are insufficient for early detection, leading to late-stage diagnoses in most patients. Liver biopsy remains the diagnostic gold standard but is invasive, costly, and prone to high inter- and intra-reader variability, limiting its utility in routine car

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Egresi, Anna, Anna Blázovics, Gabriella Lengyel, et al. "Redox Homeostasis and Non-Invasive Assessment of Significant Liver Fibrosis by Shear Wave Elastography." Diagnostics 14, no. 17 (2024): 1945. http://dx.doi.org/10.3390/diagnostics14171945.

Повний текст джерела

Анотація:

Hepatic fibrosis with various origins can be estimated non-invasively by using certain biomarkers and imaging-based measurements. The aim of our study was to examine redox homeostasis biomarkers and liver stiffness measurements for the assessment of significant liver fibrosis in different etiologies of chronic liver diseases. A cohort study consisting of 88 chronic liver disease patients of both sexes (age 49.1 ± 14.7 years) was performed. Cytokine profiles as well as redox homeostasis characteristics were determined. Liver fibrosis stages were assessed with shear wave elastography. The plasma

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Patel, Preya Janubhai, Declan Connoley, Freya Rhodes, Ankur Srivastava, and William Rosenberg. "A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 57, no. 1 (2019): 36–43. http://dx.doi.org/10.1177/0004563219879962.

Повний текст джерела

Анотація:

The rising incidence of chronic liver disease continues to be an increasing health burden. The morbidity and mortality associated with chronic liver disease typically occur in patients with advanced fibrosis. Hence, early identification of those at-risk is of vital importance to ensure appropriate ongoing management. Currently, tools for appropriate risk stratification remain limited. Increasing awareness of the limitations of liver biopsy has driven research into alternative non-invasive methods of fibrosis assessment including serological markers assessing functional changes. One such biomar

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Aslam, Hunain, Fouzia Oza, Khalid Ahmed, et al. "The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review." International Journal of Molecular Sciences 24, no. 4 (2023): 3487. http://dx.doi.org/10.3390/ijms24043487.

Повний текст джерела

Анотація:

Liver disease is one of the leading public health problems faced by healthcare practitioners regularly. As such, there has been a search for an inexpensive, readily available, non-invasive marker to aid in monitoring and prognosticating hepatic disorders. Recently, red blood cell distribution width (RDW) has been found to be associated with various inflammatory conditions with implications for its use as a potential marker for assessing disease progression and prognosis in multiple conditions. Multiple factors effect red blood cell production whereby a dysfunction in any process can lead to an

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Cho, Eun Hye, Jee Ah Kim, Min-Seung Park, Min-Jung Kwon, Hyosoon Park, and Hee-Yeon Woo. "Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease." PLOS ONE 20, no. 2 (2025): e0318847. https://doi.org/10.1371/journal.pone.0318847.

Повний текст джерела

Анотація:

Introduction Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Accurate assessment of liver fibrosis is essential for the prognosis and management of NAFLD. Mean platelet volume (MPV), an index of platelet activation, has been associated with liver fibrosis in various chronic liver diseases; however, its role in NAFLD remains uncertain. Methods This study analyzed data from 70,830 patients with NAFLD who underwent a comprehensive health examination between 2015 and 2019. Patients were stratified into three groups based on the fibrosis-4 (

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Chronic liver disease and Non invasive marker"

1

Parkes, Dr Julie. "Non-invasive biomarkers in chronic liver disease." Thesis, University of Southampton, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.509473.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Tanwar, Sudeep. "Stratified medicine : an exploration of the utility of non-invasive serum markers for the management of chronic liver diseases." Thesis, University College London (University of London), 2018. http://discovery.ucl.ac.uk/10051324/.

Повний текст джерела

Анотація:

Chronic liver disease (CLD), the 3rd commonest cause of premature death in the UK, is detected late when interventions are often ineffective. Non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CHC) account for a significant proportion of CLD in the UK. Numerous direct (molecules involved in matrix biology) and indirect biomarkers (standard laboratory tests) have been successfully developed to detect advanced liver fibrosis. Less success, however, has been achieved in the detection of alternative diagnostic targets such as early stage fibrosis, non-alcoholic steatohepatitis (NAS

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Harman, David J. "The identification of chronic liver disease in primary care using non-invasive diagnostics within a novel pathway." Thesis, University of Nottingham, 2017. http://eprints.nottingham.ac.uk/36459/.

Повний текст джерела

Анотація:

Introduction: Deaths due to chronic liver disease have increased significantly in recent decades. This is due to increases in alcohol consumption and obesity during this time period, and insensitive screening tests (liver function blood tests) utilised in primary care. This thesis describes a new liver disease community diagnostic pathway which focussed upon defined risk factors for chronic liver disease and uses Transient Elastography (TE) as the primary investigation modality. The aims of the thesis are to assess the feasibility of this pathway for detecting liver disease due to alcohol or n

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Lin, Yi-Fan, and 林宜範. "A non-invasive measurement of skin autofluorescence as a marker of advanced glycation end products accumulation in chronic renal disease patients." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/8atd3j.

Повний текст джерела

Анотація:

碩士<br>中原大學<br>生物醫學工程研究所<br>104<br>The accumulation of advanced glycation end products (AGEs) is thought to play a role in the pathogenesis of chronic complications of diabetes mellitus (DM) and renal failure. Cardiovascular diseases are the predominant causes of death in patients with end-stage renal disease undergoing hemodialysis. Skin autofluorescence (Skin AF) measurement is a non-invasive method for assessing accumulation of tissue AGEs. The aim of this study is to establish the reference curve of Skin AF for the Taiwan population and use the clinical data to determine the factors affecti

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Tsaknakis, Birgit. "Evaluation der sonographischen Gallenblasenwanddicke als neuer nicht-invasiver Marker für das Vorliegen von Ösophagusvarizen." Doctoral thesis, 2020. http://hdl.handle.net/21.11130/00-1735-0000-0005-14A7-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Chronic liver disease and Non invasive marker"

1

Plebani, Mario, Monica Maria Mion, and Martina Zaninotto. Biomarkers of renal and hepatic failure. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0039.

Повний текст джерела

Анотація:

In the last few years, major advances have been achieved in the understanding of the molecular and pathophysiological mechanisms which underlie the complex interactions between the heart and the kidney, as well as between the heart and the liver. According to these new insights, new biomarkers have been proposed for better evaluating and monitoring patients affected by cardiovascular diseases. In addition, some biomarkers should be used as risk factors and for an early identification and treatment of these severe diseases. This chapter reviews the most important biomarkers for evaluating the ‘

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Chronic liver disease and Non invasive marker"

1

Sporea, Ioan, Raluca Lupușoru, and Roxana Șirli. "Ultrasound Based Elastography Techniques for the Evaluation of Nonalcoholic Liver Disease." In Elastography - Applications in Clinical Medicine [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.102363.

Повний текст джерела

Анотація:

The number of NAFLD patients is increasing in the developed world and non-invasive modalities for their evaluation are needed. Ultrasound-based methods are very useful for this approach, starting with standard ultrasound used for steatosis detection, and continuing with new modalities for steatosis, fibrosis, and inflammation quantification. Modern ultrasound systems can quantify all these parameters in NAFLD patients, thus making ultrasound a real Multiparameter Ultrasound (MPUS). The performance of ultrasound-based methods is very well documented with liver stiffness assessment as a marker o

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Hădăreanu, Diana-Ruxandra, Cristina Florescu, Anca Mihu-Marinescu, et al. "Perspective Chapter: Metabolic Dysfunction-Associated Steatotic Liver Disease as an Emerging Cardiovascular Risk Factor – Pathophysiology, Implications and Clinical Perspectives." In Steatosis - Causes and Treatment [Working Title]. IntechOpen, 2025. https://doi.org/10.5772/intechopen.1011513.

Повний текст джерела

Анотація:

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease globally and is now recognized as a key cardiometabolic disorder. Beyond hepatic involvement, MASLD is independently associated with increased risks of coronary artery disease, stroke, arrhythmias, and heart failure, even after adjusting for traditional cardiovascular risk factors. Its pathophysiology involves insulin resistance, visceral adiposity, systemic inflammation, and oxidative stress, which collectively contribute to both hepatic fibrosis and cardiovascular disease

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Cerda-Reyes, Eira, Alicia Sarahi Ojeda-Yuren, Julián Torres-Vazquez, et al. "Diagnosis of Nonalcoholic Steatohepatitis." In Advances in Hepatology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96281.

Повний текст джерела

Анотація:

The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased in the last years up to 25% in the adult population. This disease includes a large spectrum of disorders, from simple fatty liver disease to cirrhosis and Hepatocellular Carcinoma (HCC), and they are related to chronic metabolic conditions. NAFLD is characterized by the presence of at least 5% of hepatic steatosis without evidence of hepatocellular injury. The diagnosis of this disease should be of exclusion and focused on its progression, treatment, and identification of the prognosis. The European Association for the S

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Plebani, Mario, Monica Maria Mion, and Martina Zaninotto. "Biomarkers of renal and hepatic failure." In The ESC Textbook of Intensive and Acute Cardiovascular Care, edited by Marco Tubaro, Pascal Vranckx, Eric Bonnefoy-Cudraz, Susanna Price, and Christiaan Vrints. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198849346.003.0036.

Повний текст джерела

Анотація:

In the last years, major advances have been achieved in the understanding of the molecular and pathophysiological mechanisms which underlie the complex interactions between the heart and the kidney, as well as between the heart and the liver. According to these new insights, innovative biomarkers have been proposed for better evaluating and monitoring patients affected by cardiovascular diseases. In addition, some biomarkers should be used as risk factors and for an early identification and treatment of these severe diseases. This chapter reviews the most important biomarkers for evaluating th

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Mehta, Gautam, and Bilal Iqbal. "Abdomen System." In Clinical Medicine for the MRCP PACES. Oxford University Press, 2010. http://dx.doi.org/10.1093/oso/9780199542550.003.0008.

Повний текст джерела

Анотація:

1. Jaundice is a marker of severity of liver disease, as well as a consequence of decompensation. Yellow discolouration is not usually seen until the serum bilirubin is >40μmol/L (twice the upper limit of normal), although the earliest signs of jaundice can be detected in the periphery of the conjunctivae, or in the buccal mucosa. Remember, there are other causes of jaundice in liver disease, such as Zieve’s syndrome (haemolysis and hyperlipidaemia in alcohol misuse), or biliary obstruction. 2. Cachexia can be established by demonstrating muscle and fat loss. Wasting of the temporalis muscl

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Santos, Joelma Carvalho, Caroline Louise Diniz Pereira, Ana Lúcia Coutinho Domingues, and Edmundo Pessoa Lopes. "Hepatic and splenic evaluation by ultrasonography and elastography of fibrosis and portal hypertension in Schistosomiasis mansoni." In GLOBAL HEALTH TRENDS AND PERSPECTIVES IN HEALTH SCIENCES. Seven Editora, 2023. http://dx.doi.org/10.56238/globalhealthprespesc-025.

Повний текст джерела

Анотація:

Schistosomiasis is a neglected tropical disease and an important public health problem, mainly due to its magnitude and transcendence. Although most cases are characterized as a mild infection, due to its morbidity, the untreated disease can cause economic burden and incapacitation. Periportal fibrosis (PPF) is the most common complication of schistosomiasis mansoni chronic infection and a large number of deaths are mainly caused by the rupture of esophageal varices resulting from portal hypertension (non-cirrhotic). Regarding the diagnosis and assessment of PPF and portal hypertension, differ

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Hurriyet Cetinok. "Related Anatomy of Gastrointestinal, Endocrine, Urinary, Nervous System and Morphometric Evaluation in Metabolic Syndrome." In Metabolic Syndrome: A Comprehensive Update with New Insights. BENTHAM SCIENCE PUBLISHERS, 2025. https://doi.org/10.2174/9789815322132125010008.

Повний текст джерела

Анотація:

Being overweight, hyperlipidemia, hypertension, type II diabetes mellitus(DM) or high blood sugar, and glucose intolerances are all clinical disorders collectively referred to as the metabolic syndrome (MetS). MetS affects multiple systems in the body, including cardiovascular, endocrine, urinary, nervous, and gastrointestinal systems. Atherosclerosis risk is increased by chronic inflammation and vascular endothelial dysfunction, which are both closely related to MetS. The risk of cardiovascular illnesses, the world's leading cause of mortality, is also increased by metabolic syndrome. Cancers

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Chronic liver disease and Non invasive marker"

1

Khare, Shivam, Anil Arora, Praveen Sharma, and Shashi Dhawan. "IDDF2018-ABS-0133 Performance of non-invasive blood parameters for detecting significant liver fibrosis in patients with chronic hepatitis b." In International Digestive Disease Forum (IDDF) 2018, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfabstracts.217.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Jachs, M., L. Hartl, B. Simbrunner, et al. "Non-invasive surrogates for portal hypertension show comparable prognostic value to the hepatic venous pressure gradient in compensated advanced chronic liver disease." In 56. Jahrestagung & 33. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie – ÖGGH & ˶Pre˵ Symposium der young ÖGGH. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1769019.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Liu, Yuan, Hongwei Ren, Jinghui Dong, et al. "IDDF2025-ABS-0288 Non-invasive prediction of liver inflammation grade in chronic hepatitis B patients based on DWI combined with T2WI signal intensity index." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 5 – 6 July 2025. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2025. https://doi.org/10.1136/gutjnl-2025-iddf.169.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Haghnejad, Vincent, Jessica E. Shearer, Laura Burke, Richard Parker, James Ferguson, and Ian AC Rowe. "P70 Evaluating strategies for patient selection in NSBB treatment for chronic advanced compensated liver disease: a comparative study of varices and non-invasive tests." In Abstracts of the British Association for the Study of the Liver Annual Meeting, 8–11 October 2024. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2024. http://dx.doi.org/10.1136/gutjnl-2024-basl.79.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Thorp, Rebecca Dantas, Andrea Dória Batista, Carolline de Araújo Mariz, et al. "Evaluation of liver fibrosis in Schistosomiasis Mansoni using the Enhanced Liver Fibrosis Score." In Resumos do 56º Congresso Brasileiro de Patologia Clínica/Medicina Laboratorial. Zeppelini Editorial e Comunicação, 2024. https://doi.org/10.5327/1516-3180.142s1.12215.

Повний текст джерела

Анотація:

Objective: Assessing the presence and pattern of periportal fibrosis (PPF) in schistosomiasis mansoni (SM) is essential for diagnosing clinical forms of the disease and detecting portal hypertension. Ultrasound (US) using the Niamey classification is the gold standard for this purpose; however, it requires sophisticated equipment and well-trained operators. Enhanced Liver Fibrosis (ELF) score is an index capable of quantifying liver fibrosis in chronic liver diseases. This work aimed to assess serum ELF levels according to PPF patterns established by the US/Niamey classification in SM patients

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Berezovscaia, Elena. "Evaluarea stării de sănătate a pacienților cu hepatopatii cronice cu ajutorul indicatorilor fiziologici." In "Fiziologia şi sănătatea", congresul fiziologilor. Bulletin of the Academy of Sciences of Moldova. Medical Sciences, 2025. https://doi.org/10.52692/cfzl2024.11.

Повний текст джерела

Анотація:

Chronic hepatopathies present one of the important medical issues in Moldova having leading place in terms of incidence and severity. The aim: to study physiological indices in patients with chronic hepatopathies. There were examined 59 patients: 34 - with chronic HBV infection (HBV gr.), 25 - with associated metabolic steatosis liver disease (MASLD gr.), 26 apparently healthy people entered the control group (CG). The indices of systolic (APs) and diastolic (APd) arterial pressure, pulse rate (RPs) and Kerdo Vegetative Index (KVI) were evaluated. The APs average values in the MASLD gr. were 1

Стилі APA, Harvard, Vancouver, ISO та ін.

7

George, Stephanie M., Diego R. Martin, and Don P. Giddens. "Hemodynamic Investigation of Flow in the Normal Portal Vein." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193090.

Повний текст джерела

Анотація:

Cirrhosis is the twelfth leading cause of death in the United States (1). Previous studies have compared portal vein blood flow and velocity in normal subjects and patients with varying results (2–5). In comparing grades of cirrhosis, based on the “Child-Pugh” score, portal flow was significantly affected as the degree of cirrhosis increased (2–4). These previous studies have used a variety of imaging methods; the most common being Doppler Ultrasound (2–5). The use of Magnetic Resonance Imaging (MRI) and phase contrast (PC) – MRI has not been used extensively to study liver hemodynamics. When

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Chronic liver disease and Non invasive marker"

1

Sowjanya, Dr Kaniti, Dr Bongu Srinivas, and Dr Metta Lakshmana Rao. A STUDY ON FIBROSCAN COMPARED TO AST TO PLATELET RATIO INDEX(APRI) FOR ASSESSMENT OF LIVER FIBROSIS WITH NONALCOHOLIC FATTY LIVER DISEASE(NAFLD). World Wide Journals, 2023. http://dx.doi.org/10.36106/ijar/1606016.

Повний текст джерела

Анотація:

Background : Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a cause of chronic liver disease, and often results in the devastating outcomes of decompensated liver cirrhosis and hepatocellular carcinoma and is an important feature of metabolic syndromes and insulin resistance. The assessment of liver brosis is essential for predicting the prognosis and outcome of all forms of chronic liver disease. A liver biopsy is the gold standard for the assessment of liver brosis, but it has its limitations, which include life-threatening complications. Alternative methods of non-

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!